Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Oncolytics Biotech Inc

NASDAQ: ONCY · Life Sciences · 10 alerts · CIK 1129928

Share price
$0.3399Close, Nov 16
Market cap
$46.3M
Shares outstanding
136.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oncolytics Biotech Inc filings on SEC EDGAR ↗

9:49 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.

9:37 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from an ongoing Phase 1/2 study of pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer (SCAC). The data showed that the treatment more than doubled immune activation levels in nearly all patients and expanded HPV-16-specific T cell clones, which was associated with tumor shrinkage and objective responses.

9:46 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab for squamous cell anal cancer (SCAC). The study demonstrated a median duration of response of approximately 15 months, with 100% of responding patients surviving longer than one year, supporting a potential registration path in HPV-driven cancers.

9:35 AM ET 8-K
Clinical Trial Data

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced the publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating that its immunotherapy candidate, pelareorep, can transform immunologically inactive liver cancer tumors into active ones. The data showed pelareorep increased CD8+ T cell density and PD-L1 expression, potentially making challenging tumor types more susceptible to checkpoint inhibitors and other immunotherapies.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.